Calcium

被引:269
作者
Bushinsky, DA [1 ]
Monk, RD
机构
[1] Univ Rochester, Strong Mem Hosp, Sch Med & Dent, Rochester, NY 14642 USA
[2] Univ Rochester, Strong Mem Hosp, Nephrol Unit, Rochester, NY 14642 USA
关键词
D O I
10.1016/S0140-6736(97)12331-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Abnormalities in serum calcium concentration may have profound effects on neurological, gastrointestinal, and renal function. Maintenance of the normal serum calcium is a result of tightly regulated ion transport by the kidney, intestinal tract, and bone, mediated by calcaemic hormones especially parathyroid hormone and 1,25-dihydroxyvitamin D-3. Abnormalities in calcium transport that result in uncompensated influx into, or efflux from, the extracellular fluid, will result in hypercalcaemia or hypocalcaemia, respectively. When possible the biologically important ionised calcium concentration should be measured. A variety of common disorders are responsible for abnormalities in the serum calcium. Treatment of both hypercalcaemia and hypocalcaemia is dependent on the underlying disorder, the magnitude of the deviation of the serum calcium, and the severity of symptoms. Fortunately, in the case of hypercalcaemia, there is a broad selection of effective medications, especially the bisphosphonates. Treatment of hypocalcaemia relies on the provision of calcium and often vitamin D. In this article we review the mechanisms responsible for abnormalities in calcium homoeostatisis, the differential diagnosis of hypercalcaemia and hypocalcaemia and appropriate therapy.
引用
收藏
页码:306 / 311
页数:6
相关论文
共 30 条
  • [1] Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma
    Berenson, JR
    Lichtenstein, A
    Porter, L
    Dimopoulos, MA
    Bordoni, R
    George, S
    Lipton, A
    Keller, A
    Ballester, O
    Kovacs, MJ
    Blacklock, HA
    Bell, R
    Simeone, J
    Reitsma, DJ
    Heffernan, M
    Seaman, J
    Knight, RD
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (08) : 488 - 493
  • [2] BILEZIKIAN JP, 1992, NEW ENGL J MED, V326, P1196
  • [3] MANAGEMENT OF HYPERCALCEMIA
    BILEZIKIAN, JP
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1993, 77 (06) : 1445 - 1449
  • [4] Use of bisphosphonates in cancer patients
    Body, JJ
    Coleman, RE
    Piccart, M
    [J]. CANCER TREATMENT REVIEWS, 1996, 22 (04) : 265 - 287
  • [5] Broadus Arthur E., 1996, P57
  • [6] SEMINARS IN MEDICINE OF THE BETH-ISRAEL-HOSPITAL, BOSTON - CALCIUM-ION-SENSING CELL-SURFACE RECEPTORS
    BROWN, EM
    POLLAK, M
    SEIDMAN, CE
    SEIDMAN, JG
    RICCARDI, D
    HEBERT, SC
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (04) : 234 - 240
  • [7] CLONING AND CHARACTERIZATION OF AN EXTRACELLULAR CA2+-SENSING RECEPTOR FROM BOVINE PARATHYROID
    BROWN, EM
    GAMBA, G
    RICCARDI, D
    LOMBARDI, M
    BUTTERS, R
    KIFOR, O
    SUN, A
    HEDIGER, MA
    LYTTON, J
    HEBERT, SC
    [J]. NATURE, 1993, 366 (6455) : 575 - 580
  • [8] INCREASED SERUM LEVELS OF A PARATHYROID HORMONE-LIKE PROTEIN IN MALIGNANCY-ASSOCIATED HYPERCALCEMIA
    BUDAYR, AA
    NISSENSON, RA
    KLEIN, RF
    PUN, KK
    CLARK, OH
    DIEP, D
    ARNAUD, CD
    STREWLER, GJ
    [J]. ANNALS OF INTERNAL MEDICINE, 1989, 111 (10) : 807 - 812
  • [9] THE CONTRIBUTION OF ACIDOSIS TO RENAL OSTEODYSTROPHY - DISCUSSION
    BUSHINSKY, DA
    MADIAS, NE
    HARRINGTON, JT
    KING, A
    LEMAY, S
    PARKER, M
    [J]. KIDNEY INTERNATIONAL, 1995, 47 (06) : 1816 - 1832
  • [10] BUSHINSKY DA, 1992, DISORDERS BONE MINER, P417